NTLA

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

You have to admire Cathie Wood's ability to make something good out of a bad situation. The Ark Invest co-founder and CEO often adds to some of her favorite positions when they are out of favor. She did it again this week.

Wood spent the first trading day of this week actively buying stocks that recently disappointed investors. She added to her stakes in Roku (NASDAQ: ROKU), 10x Genomics (NASDAQ: TXG), and Intellia Therapeutics (NASDAQ: NTLA). Let's take a closer look at these three purchases.

1. Roku

It's been a rough run over the past two weeks for Roku. Shares of the streaming video specialist have plummeted 35% over the past nine trading days. Three big events have marked its fall from grace.

  • The initial hit came on a report that Walmart was in talks to acquire Vizio, a move that would turn a retail partner into a platform competitor.
  • Roku followed with its own bad news, putting out poorly received fourth-quarter results. Average revenue per user saw a surprising sequential decline.
  • Walmart would go on to officially announce a $2.3 billion deal to buy Vizio.

It's been tough sledding for a stock that was hitting fresh 52-week highs in December following a blowout quarterly report the month before. Investing is a lot like the TV market, in that you're only as good as your latest season.

A couple relaxing in front of the TV.

Image source: Getty Images.

Roku remains one of Wood's largest holdings. Even after losing more than a third of its value over the past two weeks, the streaming service stock is her fifth-largest position across all of Ark Invest's holdings.

Roku continues to grow in popularity. There are now 80 million active accounts on the platform, and "active" is the key term there. The average home is now spending more than four hours per day streaming through the Roku operating system. Profitability remains a challenge, but its operating loss narrowed substantially in its latest report. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) turned positive in the second half of last year.

The shares might not rebound right away. Cautious investors may wait for average revenue per user to bounce back or for the Walmart buyout of Vizio to play out. However, Roku continues to have a commanding lead of the connected TV ad revenue being generated from streaming hubs. It's not a bad place to be despite the recent stock swoon.

2. 10x Genomics

Another Ark Invest holding that failed to impress the market with its latest quarterly update this month is 10x Genomics. The life sciences specialist, which helps researchers analyze tissue at the individual cell level, posted mixed fourth-quarter results two weeks ago. Revenue may have clocked in just ahead of expectations, but for the fourth time in a row it posted a larger deficit on the bottom line than what Wall Street pros were targeting.

It gets worse. 10x Genomics initiated guidance for 2024, calling for revenue of $670 million to $690 million in the year ahead. After seeing its top line move 20% higher in 2023, the new outlook translates to an 8% to 12% increase. The analyst consensus was hovering around $702 million in revenue. At least three analysts would go on to lower their price targets on 10x Genomics after the uninspiring report and even more problematic guidance.

3. Intellia Therapeutics

Intellia Therapeutics posted disappointing financial results last week. The gene-editing specialist reported a slightly larger-than-expected deficit in its latest quarter. It's not posting meaningful revenue at this point as it works its way through clinical-phase trials for some promising therapies.

Thankfully, the company has a cash-rich balance sheet to see it through this phase of cash burning. Its market cap is $900 million more than its enterprise value. Wood is a big believer in Intellia. She owns more than 10% of the upstart's total shares outstanding.

Not everyone is convinced. Analysts reacted largely unfavorably on Friday after last week's quarterly update. One analyst went on to downgrade the stock while another slashed their price target on the shares.

Should you invest $1,000 in Intellia Therapeutics right now?

Before you buy stock in Intellia Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intellia Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

See the 10 stocks

*Stock Advisor returns as of February 26, 2024

Rick Munarriz has positions in Roku. The Motley Fool has positions in and recommends 10x Genomics, Intellia Therapeutics, Roku, and Walmart. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.